CMed Aesthetics: Italian innovators in aesthetic excellence

CMed Aesthetics is an emerging leader in professional skincare solutions in Australia and New Zealand.

CMed Aesthetics S. p. A. (Italy), (‘CMed’) is on a mission is to revolutionise the fields of aesthetic medicine, dermatology and plastic surgery.

CMed invests significantly in research and development to advance aesthetic treatments through novel and ground-breaking products. The company has developed several patented medical inventions, including the global patented biphasic technology and a pioneering sterilisation method, more generally known as BioRePeelCl3®.

CMed’s core values are founded on integrity, safety, product excellence and customer-centricity. CMed adheres to stringent pharmaceutical standards to ensure the highest levels of quality and safety. Products undergo rigorous testing and scrutiny, guaranteeing their efficacy and reliability.

Their vision is to be a catalyst for positive change in the industry, driving innovation and setting new standards of safety and excellence.

With a global footprint spanning over 80 countries, CMed serves healthcare professionals and patients worldwide.

Company certifications

• ISO 13485: Ensuring compliance with international quality management standards for medical devices.
• ISO 22716: Certifying adherence to good manufacturing practices for cosmetics and personal care products.
• WHA-HALAL: Recognition of commitment to producing products that meet the highest standards of quality and ethical practices.

History of CMed Aesthetics

CMed founders Carlo Michellini B.Sc. (Chemistry), M.Sc. (Chemistry) and Andrea Malventi, B.Sc. (Chemistry), met in 2010, playing basketball for a team in Liguria near La Spezia, Italy. They discovered they were both studying the same tertiary course at Pisa University, and both graduated in 2015.

CMed Aesthetics S. p. A. (Italy) (CMED) was founded in August 2017. In that same year the patent for BioRePeelCl3® biphasic technology was lodged and the product is now protected by global patents.

At the beginning of 2018 CMed manufactured and shipped the first batches of BioRePeelCl3® to local doctors in Tuscany. By the end of the 2019, CMed was distributing to more than 20 countries.

In 2020 growth abated with the global pandemic. The lull enabled CMed to develop the current product line, and to purchase and establish warehousing and manufacturing facilities. Today CMed employs 32 highly skilled staff, with two new production facilities under development, and ground-breaking CE-accredited products to be announced shortly.

CMed Aesthetics ANZ – about the Australian/New Zealand distributor

CMed Aesthetics ANZ (“CMed ANZ”) is wholly Australian owned, with warehousing, administration and operations located in Melbourne, Victoria. Before accepting the privilege of representing CMed in Australia and New Zealand, a thorough evaluation and testing focused on the four key pillars of safety, efficacy, quality and compliance. Extensive stress testing validated the safety, efficacy and robustness of BioRePeelCl3® with particular focus on compliance with Australian and New Zealand regulations.

CMed ANZ provides support through an in-house team of medical and dermal practitioners and nationally through a team of agents trained to conduct on-site product demonstrations and support. Advanced treatment protocols are being progressively evaluated with advanced training program launching in Australia shortly, with plans for New Zealand to follow shortly.